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CD26/dipeptidyl peptidase IV (DPPIV) is a surface antigen with multiple functions, including a role in T-cell activation and the
development of certain human cancers. We previously demonstrated that CD26/DPPIV enhanced sensitivity of Jurkat cells to
doxorubicin. We now show that expression of CD26/DPPIV enhanced sensitivity of CD26 Jurkat transfectants to G2–M arrest
mediated by the antineoplastic agent etoposide. The increased sensitivity to etoposide-induced G2–M arrest was associated with
disruption of cell cycle-related events, including hyperphosphorylation of p34
cdc2 kinase, change in cdc25C expression and
phosphorylation, and alteration in cyclin B1 expression. CD26/DPPIV-associated enhancement of doxorubicin and etoposide-
induced G2–M arrest was also observed in serum-free media, suggesting an effect of CD26 on cell-derived processes rather than
serum-derived factors. Importantly, our work elucidated a potential mechanism for the enhanced susceptibility of CD26-expressing
Jurkat cells to the topoisomerase II inhibitors by demonstrating that CD26/DPPIV surface expression was associated with increased
topoisomerase II a levels and enhanced enzyme activity. Besides being the first to show a functional association between the
multifaceted molecule CD26 and the key cellular protein topoisomerase II a, our studies provide additional evidence of a potential
role for CD26 in the treatment of selected malignancies.
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CD26 is a 110kDa surface glycoprotein with diverse functional
properties and is expressed on a variety of tissues, including
selected lymphoid cells (Morimoto and Schlossman, 1998). Its
extracellular domain encodes a membrane-associated dipeptidyl
peptidase IV (DPPIV) activity, able to cleave amino-terminal
dipeptides from polypeptides with either L-proline or L-alanine at
the penultimate position, including chemokines involved in
leukocyte function (Oravecz et al, 1997; Proost et al, 1998).
CD26 is also involved in T-cell activation, owing to its association
with CD45, mannose 6-phosphate/insulin-like growth factor II
receptor and adenosine deaminase (ADA) (Morimoto et al, 1989;
Dang et al, 1990a–d, 1991; Torimoto et al, 1991; Kameoka et al,
1993; Morrison et al, 1993; Ikushima et al, 2000). Additionally, its
DPPIV enzyme activity has a key role in various aspects of T-cell
activation, as demonstrated by studies using DPPIV inhibitors,
soluble CD26/DPPIV molecules or CD26 genetic mutants (Flentke
et al, 1991; Tanaka et al, 1993, 1994; Steinbrecher et al, 2001).
Besides its involvement in normal T-cell function, CD26 may also
have a role in the development of certain tumors (Tanaka et al,
1995; Stecca et al, 1997; Bauvois et al, 1999; Dang and Morimoto,
2002). For example, it is expressed on the surface of such
aggressive T-cell malignancies as T-cell lymphoblastic lymphomas/
acute lymphoblastic leukaemias and T cell CD30+ anaplastic large
cell lymphomas, but not on the more indolent T-cell diseases like
mycosis fungoides (Carbone et al, 1995; Jones et al, 2001).
Based on our hypothesis that CD26 expression influences
tumour cell biology and potentially its sensitivity to cytotoxic
treatments, as suggested by previous work showing that CD26
expression is associated with changes in tumour cell line behaviour
in vitro and that the clinical behaviour of selected tumours may be
correlated with differences in CD26 expression (Morrison et al,
1993; Carbone et al, 1995), we initiated studies using stable CD26
Jurkat transfectants to investigate the effect of CD26 on tumour
sensitivity to selected antineoplastic agents. We recently demon-
strated that Jurkat cells expressing CD26/DPPIV displayed
enhanced sensitivity to cell cycle arrest induced by doxorubicin
(Aytac et al, 2001). Owing to the potential implications of our
findings with regards to future treatment of selected cancers, we
investigated the effect of CD26/DPPIV on tumour sensitivity to
etoposide, another key antineoplastic agent. In this paper, we
extend our previous work by showing that expression of
CD26/DPPIV resulted in enhanced sensitivity to etoposide-
induced G2–M arrest, associated with such changes of key
regulators of this checkpoint as hyperphosphorylation of p34
cdc2,
change in expression and phosphorylation of cdc25C and
alteration in cyclin B1 expression. Furthermore, we demonstrate
Received 25 April 2002; revised 7 November 2002; accepted 22
November 2002
*Correspondence: Dr NH Dang, MD Anderson Cancer Center- BOX
429, 1515 Holcombe Boulevard, Houston, TX 77030, USA;
E-mail: nhdang@mail.mdanderson.org
4These authors contributed equally to this work.
British Journal of Cancer (2003) 88, 455–462
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sthat the effect of CD26/DPPIV on drug sensitivity was independent
of serum, as similar results were obtained in serum-free media.
Finally and perhaps most importantly, we establish that expression
of CD26/DPPIV resulted in enhanced levels of topoisomerase II a
that correlated with increased enzyme activity, suggesting a
potential mechanism for the observed increase in tumour
sensitivity to the topoisomerase II inhibitors doxorubicin and
etoposide.
MATERIALS AND METHODS
Cells and reagents
Human T-cell leukaemia Jurkat stable transfectants have been
described (Tanaka et al, 1993; Aytac et al, 2001). The Jurkat cell
lines include: (1) wild-type CD26-transfected Jurkat cell lines
(wtCD26); (2) Jurkat cell lines transfected with mutant CD26
containing an alanine at the putative catalytic serine residue at
position 630, resulting in a mutant CD26-positive/DPPIV-negative
Jurkat transfectant (S630A); and (3) nontransfected parental
Jurkat cells (parental). Jurkat transfectants were maintained
in culture media, which consisted of RPMI 1640 supplemented
with 10% FCS, penicillin (100Uml
 1), streptomycin (100mgml
 1),
and G418 (0.25mgml
 1) (Gibco BRL, NY, USA). Nontransfected
parental Jurkat cells were maintained in the same culture media
without G418. For certain experiments, AIM V serum-free media
(Gibco, NY, USA) were used rather than culture media containing
RPMI 1640 and 10% FCS. In experiments involving AIM V serum-
free media, cells were washed extensively with sterile PBS, and then
preincubated for 24h at 371C with AIM V-containing culture
media to prevent contamination with serum. Following preincuba-
tion, cells were washed with sterile PBS, and then further incubate
in AIM V-containing culture media with or without chemother-
apeutic agents at the indicated doses. Anti-p34
cdc2, anti-cdc25C
and anti-cyclin B1 were from Santa Cruz (CA, USA), antitopo-
isomerase II a (Ki-S1, recognising a carboxyterminal a-isozyme
specific epitope) was from Boehringer Mannheim, antiactin was
from Sigma, and the anti-CD26 antibody 1F7 was a murine
antibody that has been described previously (Morimoto et al,
1989). Tetrazolium salt MTT (3,(4,5-dimethylthiazol-2-yl)2,5-
diphenyltetrazolium bromide) (Sigma, MO, USA) was dissolved
at a concentration of 5mgml
 1 in sterile PBS at room temperature,
with the solution being filter sterilized and stored at 41C in the
dark. Extraction buffer was prepared as follows: 20% wv
 1 of SDS
was dissolved at 371C in a solution of 50% each of N,N-dimethyl
formamide (DMF) (Sigma, MO, USA) and distilled water; pH was
adjusted to 4.7 by the addition of 1 M HCl. Etoposide and
doxorubicin were purchased from Calbiochem and was dissolved
in sterile PBS. Hybond N
+ membrane, [a-
32P]dCTP and the Ready-
To-Go DNA labelling beads were obtained from Amersham
Biosciences. Human topoisomerase IIalpha gene probe YEpWob6
was kindly provided by Dr Leroy F Liu (Robert Wood Johnson
Medical School, NJ, USA).
MTT assay
Cell growth assay was performed as described previously (Aytac
et al, 2001). Cells were incubated in microplates in the presence of
culture media alone, culture media and doxorubicin or etoposide
at the indicated concentrations for a total volume of 100ml
(50000cellswell
 1). Following 36–48h of incubation at 371C, 25ml
of MTT was added to the wells at a final concentration of
1mgml
 1. The microplates were then incubated for 2h at 371C,
followed by the addition of 100ml of extraction buffer. Following
overnight incubation at 371C, OD measurements at 570nm were
performed, with the s.e. of the mean of the triplicate wells being
less than 15%. Cytotoxicity index was calculated as follows:
Cytotoxicityindexð%of controlÞ
¼ 1  
OD570nm of treatedcells
OD570nm of controlcells
 100%:
Cell cycle analysis
Cells were incubated in culture media alone, culture media and
doxorubicin or etoposide at indicated concentrations at 371C for
24h. Cells were then collected, washed twice with PBS and
resuspended in PBS containing 10mgml
 1 propidium iodide, 0.5%
Tween-20 and 0.1% RNase at room temperature for 30min.
Samples were then analysed (FACScan, Becton Dickinson, CA,
USA) for DNA content. Cell debris and fixation artefacts were
gated out and G0–G1, S, and G2–M populations were quantified
using the CellQuest and ModFit LT programs.
Sodium dodecyl – polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting
After incubation at 371C in culture media and doxorubicin or
etoposide at the concentrations indicated for 24h, cells were
harvested from wells, washed with PBS and lysed in lysis buffer,
consisting of 1% Brij 97, 5mM EDTA, 0.02 M HEPES, pH 7.3, 0.15 M
NaCl, 1mM PMSF, 0.5mM NaF, 10mgml
 1 aprotinin and 0.2mM
sodium orthovanadate. After incubating on ice for 15min, nuclei
were removed by centrifugation and supernatants were collected.
2 sample buffer consisting of 20% glycerol, 4.6% SDS, 0.125 M
Tris, pH 6.8 and 0.1% bromophenol blue was added to the
appropriate aliquots of supernatants. Following boiling, protein
samples were submitted to SDS–PAGE analysis on an 8% gel
under standard conditions using a mini-Protean II system
(Bio-Rad, CA, USA). For immunoblotting, the proteins were
transferred onto nitrocellulose (Immobilon-P, Millipore, MA,
USA). Following overnight blocking at 41C in a blocking solution
consisting of 0.1% Tween-20 and 5% bovine serum albumin (BSA)
in TBS, membranes were blotted with the appropriate primary
antibodies diluted in blocking solution for 1h at room tempera-
ture. Membranes were then washed with blocking solution, and
appropriate secondary antibodies diluted in blocking solution
were then applied for 1h at room temperature. Secondary
antibodies were goat anti-mouse or goat anti-rabbit HRP
conjugates (Dako, CA, USA). Membranes were then washed with
blocking solution and proteins were subsequently detected by
chemiluminescence (Amersham Pharmacia Biotech, NJ, USA).
Detection of DPPIV enzyme activity
Dipeptidyl peptidase IV (DPPIV) enzyme activity was detected by
using an Enzyme Overlay Membrane system (EOM, Enzyme
Systems Products, Dublin, CA, USA) to which the substrate
Ala-Pro-AFC (7-amino-4-trifluoromethyl Coumarin) has been
coupled, as described previously (Aytac et al, 2001). Following
incubation at 371C with media alone or media with etoposide for
24h, cell lysates were prepared, and sample buffer consisting of
20% glycerol, 4.6% SDS, 0.125 M Tris, pH 6.8, 0.1% bromophenol
blue and 2% 2-mercaptoethanol was added at room temperature.
Samples were then submitted to SDS–PAGE analysis on an 8% gel
under standard conditions. The EOM was moistened in 0.5 M Tris
HCl, pH 7.8, placed over the surface of the gel, and incubated at
371C for 40min in a humidified atmosphere. The membrane was
then removed from the gel and placed atop a long-wavelength UV
lamp box to monitor enzymatic reaction, which involves the
removal of the dipeptide Ala-Pro from the fluorogenic AFC and
results in the appearance of fluorescent bands on the membrane.
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All procedures were carried out at 41C, and flow cytometry
analyses were performed (FACScan, Becton Dickinson, CA, USA)
as described previously (Dang et al, 1990d). Cells were stained with
anti-CD26 antibody and washed two times with PBS and then with
goat anti-mouse IgG FITC (Coulter). Cells were then washed two
times with PBS prior to flow cytometry analyses. Negative controls
were stained with second antibody alone.
Preparation of nuclear extracts for detection of
topoisomerase II a
For detection of topoisomerase II a by immunoblotting, isolation
of nuclear fractions from Jurkat cells were prepared as follows. In
brief, 10 10
6 cells were harvested and allowed to swell for 15min
on ice in cytoplasmic extraction buffer (10mM HEPES, 10mM KCL,
0.1mM EDTA, 0.1mM EGTA, 1mM DTT, 1mM PMSF, 2mgml
 1
leupeptin, 2mgml
 1 aprotinin, and 0.5mgml
 1 benzamidine).
Then NP-40 (final concentration 0.3%) was added into that cell
suspension and vortexed for 10s. After 1min of centrifugation at
16000g, the supernatant was removed. The pellet was then
incubated with nuclear extraction buffer (20mM HEPES, 400mM
KCL, 1mM EDTA, 1mM EGTA, 1mM DTT, 0.5mM PMSF, 2mgml
 1
leupeptin, 2mgml
 1 aprotinin, and 0.5mgml
 1 benzamidine) for
30min on ice with intermittent vortexing. The suspension was
centrifuged at 16000g for 5min, and supernatant was saved as the
nuclear extract. SDS–PAGE and immunoblotting were then
performed on the nuclear extracts. Each lane was equally loaded
with 15mg of protein.
Detection of topoisomerase II a activity
Topoisomerase II a catalytic activity was analysed through the use
of the topoisomerase II decatenation assay kit according to the
manufacturer’s instructions (TopoGEN, Inc, OH, USA). Briefly,
following incubation of Jurkat cells at 371C for 24h in culture
media, 10 10
6 cells were harvested and nuclear extracts were
obtained. Appropriate dilutions of nuclear extracts of Jurkat CD26
transfectants or parental Jurkat cells were then incubated with
0.2mg of kinetoplast DNA (kDNA) in a 1 Topo II assay buffer
(50mM Tris-HCl, pH 8, 120mM KCl, 10mM MgCl2, 0.5mM ATP,
0.5mM dithiothreitol, and 30mgml
 1 BSA) for 60min at 371C. The
reactions were terminated by the addition of 5 stop buffer/gel
loading dye (final concentration: 1% Sarkosyl, 0.0005% bromo-
phenol blue and 5% glycerol). DNA products were resolved on 1%
agarose gel containing ethidium bromide (0.5mgml
 1) at 50V for
60min. After electrophoresis, the gel was destained in water for
30min, and fluorescence was photographed by UV imager.
Northern blotting studies
Total RNA was isolated from Jurkat cells by using Trizol Reagent
(Life Technologies, NY, USA) according to the manufacturer’s
instructions. Then, RNA samples (20mglane
 1) were run on 1%
agarose–formaldehyde gel and transferred to a Hybond N
+
membrane for the Northern blot analysis by standard procedures.
For detection of topoisomerase II a mRNA, YEpWob6 cDNA probe
was labelled with [a-
32P]dCTP using the Ready-To-Go DNA
labelling beads (Amersham Biosciences, NJ, USA) and the blots
were hybridised with the labelled probe in ULTRAhyb buffer
(Ambion, TX, USA) for 24h at 421C. The blots were washed in
2 SSC and 0.1% SDS at 421C and then washed in 0.1 SSC and
0.1% SDS at 421C. The blots were exposed to a Phosphor Imager
screen (Molecular Dynamics Storm MD 840, NJ, USA) for 24–48h.
Statistics
Student’s t-test was used to determine whether the difference
between control (S630A and parental Jurkat cells) and wtCD26
cells was significant (Po0.05 being significant).
RESULTS
Effect of CD26/DPPIV expression on etoposide-mediated
growth inhibition and cell cycle arrest at the G2–M
checkpoint of Jurkat cells
In view of our recent findings regarding the effect of CD26/DPPIV
on sensitivity to the topoisomerase II inhibitor doxorubicin, we
examined its effect on etoposide, another topoisomerase II
inhibitor with antineoplastic activity, using stable CD26 transfec-
tants of the Jurkat T-leukaemia cell line. Figure 1 shows that
wtCD26 transfectants (wtCD26) displayed significantly increased
sensitivity to etoposide compared to parental cells, as monitored
by MTT uptake assays. Vector-only Jurkat transfectants also
exhibited the same degree of drug sensitivity as parental cells (data
not shown). Significantly, CD26 transfectants mutated at the
DPPIV catalytic site (S630A) were also less sensitive to etoposide
than wtCD26 transfectants. These data suggested that the presence
of CD26, particularly its intrinsic DPPIV enzymatic activity,
resulted in enhanced sensitivity to DNA damage mediated by the
antineoplastic agent etoposide.
Cell cycle analysis by PI staining demonstrated that the
enhancement in etoposide sensitivity seen with wtCD26 transfec-
tants as compared to parental Jurkat cells was because of an
increase in the percentage of cells arresting at G2–M (Table 1).
Once again, DPPIV enzymatic activity was required to maximise
drug sensitivity to etoposide as the G2–M block in the S630A CD26
mutant was significantly less than that seen with wtCD26
transfectants.
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Figure 1 Effect of CD26/DPPIV expression on etoposide-mediated
growth inhibition. CD26 Jurkat transfectants and parental cells were
incubated at 371C in culture media alone or culture media containing
etoposide at the concentrations indicated, and MTT uptake assay was
performed as described in Materials and Methods. wtCD26: wild-type
CD26 Jurkat transfectant; S630A: CD26-positive/DPPIV-negative mutant
CD26 Jurkat transfectant. Asterisks indicate wtCD26 samples with results
significantly different from those of S630A and parental Jurkat cells
(Po0.05). Data represent the means of three separate experiments.
Cytotoxicity index was calculated as follows:
Cytotoxicityindexð%of controlÞ
¼ 1  
OD570nm of treatedcells
OD570nm of cellsincubatedinculturemediaalone
 100%:
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transfectants
Data from Figure 2A showed that CD26 is expressed on the surface
of wtCD26 and S630A Jurkat transfectants, and is not expressed on
parental Jurkat cells. Figure 2B showed that only wtCD26 Jurkat
transfectants expressed DPPIV enzyme activity, which still remains
after treatment with etoposide. On the other hand, S630A
transfectants as well as parental Jurkat cells did not exhibit DPPIV
enzyme activity. These data therefore indicated that the observed
differences in etoposide sensitivity in these various CD26 Jurkat
transfectants were associated with differences in DPPIV enzymatic
activity.
Effect of CD26/DPPIV expression on p34
cdc2, cyclin B1 and
cdc25C following etoposide treatment of Jurkat cells
To elucidate the mechanisms involved in CD26/DPPIV-associated
enhancement in etoposide-induced G2–M arrest, we evaluated the
status of key regulators of this checkpoint (Figure 3). p34
cdc2
undergoes hyperphosphorylation at the inhibitory residues
Thr14/Tyr15 following etoposide treatment, leading to decreased
kinase activity associated with G2–M arrest (King et al, 1994; Poon
et al, 1997; Aytac et al, 2001). As assessed by Western blot analysis,
etoposide-treated wtCD26 Jurkat transfectants had higher levels of
hyperphosphorylated p34
cdc2 as compared to parental Jurkat cells
and S630A transfectants, which only exhibited a slight enhance-
ment in the level of phosphorylated p34
cdc2 at the higher doses of
etoposide.
Meanwhile, as demonstrated previously (Peng et al, 1997; Aytac
et al, 2001), lysates from asynchronously growing Jurkat cells
contained two major electrophoretic forms of cdc25C differing in
serine-216 phosphorylation. Our studies consistently showed that
wtCD26 transfectants displayed increased overall expression of
cdc25C and enhancement in cdc25C serine-216 phosphorylation as
compared to S630A transfectants and parental cells, when these
cells were treated with etoposide. The increase in cdc25C serine-
216 phosphorylation was therefore concordant with enhanced
p34
cdc2 inhibitory phosphorylation in etoposide-treated wtCD26
Jurkat transfectants as compared to parental cells or S630A
transfectants.
Our studies also showed that the levels of cyclin B1, which
associates with p34
cdc2 as part of the key complex regulating cell
cycle progression at the G2–M checkpoint, were higher in wtCD26
Jurkat transfectants as compared to those in parental cells or
S630A transfectants following treatment with etoposide. As we
previously noted (Aytac et al, 2001), we found in many
experiments that cyclin B1 levels were slightly higher in untreated
wtCD26 transfectants as compared to untreated parental cells or
S630A transfectants. Nevertheless, treatment with etoposide
consistently resulted in a significant rise in cyclin B1 level in
wtCD26 transfectants, an increase greater than that seen in
parental Jurkat cells or S630A transfectants. The relative level of
cyclin B1 expression therefore correlated with the relative
sensitivity of CD26 Jurkat transfectants to etoposide, similar to
the case seen with p34
cdc2 phosphorylation status and cdc25C
serine-216 phosphorylation.
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Figure 2 CD26 expression and DPPIV enzyme activity on Jurkat
transfectants. (A) Jurkat cells were evaluated for CD26 expression by flow
cytometry as described in Materials and Methods. panel 1: Parental Jurkat;
panel 2: S630A transfectants; panel 3: wtCD26 transfectants; a: negative
control; b: anti-CD26 antibody. (B) Jurkat cells were incubated for 24h at
371C with media alone or etoposide at 0.10mM or 0.50mM. Cells were then
harvested, and DPPIV enzyme activity assays were performed as described
in Materials and Methods. Lanes 1–3: media alone; lanes 4–6: etoposide at
0.10mM; lanes 7–9: etoposide at 0.50mM. Lanes 1, 4, 7: wtCD26; lanes 2, 5,
8: S630A; lanes 3, 6, 9: parental Jurkat cells.
Table 1 Enhanced etoposide-induced G2–M arrest associated with
CD26/DPPIV
%G0–G1 %S %G2–M
Media alone
Parental 49 38 13
S630A 47 42 11
wtCD26 46 40 14
Etoposide (0.10mM)
Parental 41 38 21
S630A 34 37 29
wtCD26 25 19 56
Etoposide (0.25mM)
Parental 27 32 41
S630A 22 30 48
wtCD26 12 19 69
CD26 Jurkat transfectants and parental cells were incubated at 371C in media
containing etoposide for 24h. Cells were then harvested and cell cycle analyses were
performed with PI staining. Data are representative of three separate experiments.
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independent of serum
CD26 is able to cleave amino-terminal dipeptides from biological
factors with either L-proline or L-alanine at the penultimate
position through its DPPIV activity to alter their physiologic
functions (Oravecz et al, 1997; Proost et al, 1998). To evaluate
the possible role of serum-derived factors in CD26-associated
enhancement in drug sensitivity, we incubated wtCD26 transfec-
tants or parental Jurkat cells in AIM V serum-free media, and
then performed similar studies as described above following
doxorubicin or etoposide treatment. We demonstrated that
the presence of CD26 still resulted in enhanced sensitivity to
drug-induced G2–M arrest in serum-free media, as assessed
by MTT uptake studies (Figure 4) and cell cycle analyses
(Table 2). Similarly, wtCD26 Jurkat transfectants exhibited
greater p34
cdc2 phosphorylation, overall expression and
serine-216 phosphorylation of cdc25C, and cyclin B1 level
when treated with etoposide or doxorubicin as compared to
parental Jurkat cells (Figure 5). Hence, these findings suggested
that the enhanced drug sensitivity associated with CD26/DPPIV
expression in CD26 Jurkat transfectants is because of its effect on
cell-derived processes rather than because of its interaction with
serum-derived factors.
CD26/DPPIV expression is associated with enhanced
topoisomerase II a level and activity
As antineoplastic agents with key role in the treatment of
haematological malignancies, doxorubicin and etoposide both
target topoisomerase II a (Burden and Osheroff, 1998). To further
explore the potential mechanism of CD26/DPPIV-associated
enhancement in drug sensitivity, we evaluated topoisomerase II
a expression in CD26 Jurkat transfectants. We found that wtCD26
Jurkat transfectants expressed higher level of topoisomerase II a
than parental Jurkat cells or S630A transfectants (Figure 6A),
showing that the increased drug sensitivity in Jurkat cells
expressing CD26/DPPIV was associated with enhanced topoisome-
rase II a level. Furthermore, we demonstrated that the enhanced
topoisomerase II a protein level correlated with increased
topoisomerase II a enzyme activity in wtCD26 Jurkat cells as
compared to S630A transfectants or parental Jurkat cells. While
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Figure 4 Enhanced sensitivity of wtCD26 to etoposide and doxorubicin in serum-free media. Following pretreatment with AIM V serum-free media at
371C for 24h, wtCD26 and parental Jurkat cells were incubated at 371C in serum-free media containing etoposide (A) or doxorubicin (B) for 48h, and
MTT uptake assays were performed as described in Materials and Methods. Asterisks indicate wtCD26 samples with results significantly different from those
of S630A and parental Jurkat cells (Po0.05). Data represent the means of three separate experiments. Cytotoxicity index was calculated as follows:
Cytotoxicityindexð%of controlÞ¼1  
OD570nm of treatedcells
OD570nm of cellsincubatedinmediaalone
 100%:
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Figure 3 Effect of CD26/DPPIV expression on p34
cdc2/cyclin B1 com-
plex and cdc25C following etoposide treatment. Jurkat cells were
incubated for 24h at 371C with media containing etoposide at the
indicated doses. Cells were then harvested, and immunoblotting studies
were performed with appropriate antibodies as described in Materials and
Methods.
Table 2 Enhanced sensitivity to etoposide and doxorubicin in serum-
free media
%G0–G1 %S %G2–M
Media alone
Parental 54 36 10
wtCD26 55 34 11
Etoposide (0.25mM)
Parental 51 30 19
wtCD26 34 23 43
Etoposide (0.50mM)
Parental 36 28 36
wtCD26 18 18 64
Doxorubicin (0.10mM)
Parental 43 30 27
WtCD26 31 20 49
Doxorubicin (0.25mM)
Parental 36 23 41
wtCD26 14 12 74
Following pretreatment with AIM V serum-free media at 371C for 24h, wtCD26
Jurkat transfectants and parental cells were incubated at 371C in serum-free media
with etoposide or doxorubicin for 24h. Cells were then harvested and cell cycle
analyses were performed with PI staining. Data are representative of three separate
experiments.
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nuclear extracts from wtCD26, S630A and parental Jurkat cells, it
was detected only in wtCD26 nuclear extracts at lower concentra-
tions (Figure 6B). On the other hand, Northern blotting studies
consistently detected similar levels of topoisomerase II a mRNA in
wtCD26, S630A and parental Jurkat cells (Figure 6C).
DISCUSSION
In this paper, we extended our earlier work by showing that the
presence of DPPIV enzymatic activity of CD26-enhanced sensitiv-
ity of the human T-leukaemia line Jurkat to etoposide-induced
DNA damage. Similar to our previous findings with the
antineoplastic agent doxorubicin (Aytac et al, 2001), we demon-
strated that etoposide exhibited greater effect on wtCD26
transfectants than parental Jurkat cells or CD26-positive/DPPIV-
negative Jurkat transfectants through its effect on major regulators
of the G2–M checkpoint, including p34
cdc2, cdc25C and cyclin B1.
We also showed that CD26-associated enhancement in sensitivity
to doxorubicin and etoposide was independent of serum-derived
factors, since similar effects were seen when cells were incubated in
the presence of serum-free media. Significantly, our studies
elucidated a potential mechanism involved in CD26/DPPIV-
associated susceptibility to doxorubicin and etoposide-induced
G2/M arrest by revealing a correlation between topoisomerase II a
activity and protein level and CD26-associated sensitivity to the
topoisomerase II inhibitors. However, we detected similar levels of
topoisomerase II a mRNA in wtCD26, S630A and parental Jurkat
cells. Results of our Northern blotting studies therefore suggested
that the observed enhancement in topoisomerase II a level seen in
Jurkat transfectants expressing CD26/DPPIV was not because of an
overall increase in the steady-state level of topoisomerase II a
mRNA. Topoisomeras II a levels are regulated through a number
of mechanisms by various factors, including transcriptional rate,
post-transcriptional alterations and post-translational modifica-
tions (Isaacs et al, 1998). Our laboratory is now actively
conducting work to elucidate the particular mechanism(s)
involved in CD26/DPPIV-associated enhancement in topoisome-
rase II a protein level and enzyme activity.
Essential for cellular proliferation as a key regulator of mitosis,
DNA topoisomerase II enzyme catalyses many types of inter-
conversions between different DNA topological isomers (Wang,
1996). Eukaryotes have two isoforms of topoisomerase II, a and b,
which are coded by two distinct genes (Drake et al, 1989). A key
factor in drug resistance is the intracellular level of topoisomerase
II a, as several studies demonstrated that increased enzyme level is
correlated with increased sensitivity, and drug resistance is often
associated with decreased topoisomerase II a level (Davies et al,
1988; Fry et al, 1991; Larsen and Skladanowski, 1998). Consistent
with these previous findings, our work showed that expression of
CD26/DPPIV in Jurkat transfectants was associated with higher
level of topoisomerase II a. While these findings suggested that a
mechanism for the enhanced sensitivity to doxorubicin and
etoposide was the increased intracellular level of their target
enzyme, our data did not necessarily exclude the potential
28S
18S
1          2          3
Topoisomerase II 
  1             2            3
Topoisomerase II 
-actin
 1    2    3    4    5    6    7    8    9  10  11  12  13 
Catenated kDNA
Decatenated kDNA
A
B
C
Figure 6 Topoisomerase II a expression, catalytic activity and mRNA
level associated with CD26/DPPIV. (A) Jurkat cells were incubated in
normal culture media, and nuclear extracts were collected for immuno-
blotting studies to evaluate topoisomerase II a protein levels as described in
Materials and Methods. Each lane was equally loaded with 15mg of protein.
Lane 1: wtCD26; lane 2: S630A cells; lane 3: parental Jurkat. Data are
representative of three separate experiments. (B) Topoisomerase II
decatenation assay was performed as described in Materials and Methods,
with nuclear extracts from wtCD26 transfectants, S630A transfectants or
parental Jurkat cells being assayed at the indicated concentrations. Lanes 1–
4: wtCD26 Jurkat transfectants; lanes 5–8: S630A Jurkat transfectants; lanes
9–12: parental Jurkat cells. Lanes 1, 5, 9: 0.85mg of nuclear extracts; lanes 2,
6, 10: 0.75mg of nuclear extracts; lanes 3, 7, 11: 0.65mg of nuclear extracts;
lanes 4, 8, 12: 0.50mg of nuclear extracts; lane 13: decatenated kDNA
marker. Data are representative of three separate experiments. (C) Total
cellular RNA (20mg) was isolated from Jurkat cells and subjected to
Northern blot analysis with a
32P-radiolabelled topoisomerase II a cDNA
probe as described in Materials and Methods. Lane 1: wtCD26 Jurkat; lane
2: S630A; lane 3: parental Jurkat. The lower panel represents ethidium
bromide staining of RNA gel prior to transfer. Data are representative of
three separate experiments.
wtCD26              Parental
Etoposide (M)     0   0.25  0.50    0   0.25  0.50
p34cdc2
Cyclin B1
cdc25C
−actin
wtCD26             Parental
Doxorubicin (M)    0    0.10  0.25   0   0.10  0.25
A B
Figure 5 Effect of CD26 expression on G2/M checkpoint regulators following drug treatment in serum-free media. Following pretreatment with AIM V
serum-free media at 371C for 24h, wtCD26 and parental Jurkat cells were incubated at 371C in serum-free media containing etoposide (A) or doxorubicin
(B) for 24h at 371C. Cells were then harvested and immunoblotting studies were conducted with appropriate antibodies as described in Materials and
Methods.
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sinvolvement of other additional factor(s) (Beck et al, 1993; Larsen
and Skladanowski, 1998). Furthermore, a functional association
between CD26 and topoisomerase II a may also prove to be an
important and generalised aspect of CD26 biology. In fact, this
interaction may play a role in CD26 function in T-cell physiology,
particularly in view of well-established findings from multiple
groups demonstrating CD26 involvement in T-cell activation and
proliferation.
CD26/DPPIV cleaves selected cytokines at the NH2 terminus to
alter their biological functions, resulting in lower chemotactic
potency, impaired signalling effects and altered receptor specificity
(Oravecz et al, 1997; Proost et al, 1998). Our studies with serum-
free media showed that the presence of CD26/DPPIV was still
associated with enhanced sensitivity to doxorubicin and etoposide,
by influencing the key components of the G2–M checkpoint
following drug treatment. These findings therefore suggested that
CD26/DPPIV affects certain intrinsic cell-derived factors, inde-
pendent of serum, to interfere with selected intracellular pathways,
leading to enhanced drug sensitivity.
Previous studies have demonstrated that CD26 is expressed on
the surface of selected aggressive T-cell malignancies (Carbone
et al, 1995; Jones et al, 2001). Meanwhile, topoisomerase II a is
highly expressed on aggressive B-cell non-Hodgkin’s lymphomas;
on the other hand, its expression on T-cell malignancies appears to
be generally low, although this conclusion is based on studies with
limited samples (Holden et al, 1995; Turley et al, 1997;
Korkolopoulou et al, 2001). Our current data with the human
T-cell leukaemia cell line Jurkat suggest that the expression of
CD26 may be potentially linked to high topoisomerase II a level in
selected T-cell malignancies, which are generally aggressive and
often difficult to treat at the present time. These findings therefore
suggest a correlation between CD26 and topoisomerase II a
expression in haematological malignancies as well as perhaps
selected solid tumours, which may also have potential clinical
implications in view of the use of topoisomerase II inhibitors as
major components of the treatment of these diseases. Along with
our recent study demonstrating in vitro and in vivo antitumour
effect of anti-CD26 antibody (Ho et al, 2001), our current work
may therefore provide additional insights into the potential
treatment strategies for selected cancers based on CD26 biology.
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